Background: Multiple Sclerosis (MS) is one of the most common diseases of the central nervous system. Previous studies have shown the cost of MS to be significantly higher than many other chronic conditions and estimated that non-VHA MS patients had a mean annual all cause health care cost of $18,829 and MS related cost of $8,839.1,2 The incremental cost of MS and factors that influence total direct medical cost among MS patients in the VHA have not been previously studied.
Objective: Estimate the annual incremental direct medical cost of MS as well as the marginal effect of demographic and clinical factors on the total direct medical cost of MS in the VHA during fiscal year 2009.
Methods: This study consisted of two aims based upon a one year cross sectional, retrospective matched control design and a generalized linear model using a VHA registry of MS patients.
Results: MS cases had a higher mean annual prescription cost than the controls ($4,885 vs $1,445), a higher mean annual cost for outpatient encounters than the controls ($5,417 vs $4,408), a higher mean annual inpatient stay cost than the controls ($32,305 vs $25,703), and had a higher mean total cost than the controls ($14,800 vs $7,381). The mean annual incremental costs for an MS patient were $ 3,254 for prescriptions, $1,168 for outpatient encounters, $12,596 for inpatient stays, which resulted in a total annual incremental cost of MS of $7,419. Individual factors associated with a positive marginal effect on the annual total direct medical cost for an individual with MS included: progressive form of MS; higher Elixhauser Conditions Score; current use of disease modifying therapy medication; and race. Level of self-reported MS related disability and educational attainment, age, age at onset, duration of MS since onset, and gender did not influence the annual total direct medical cost of MS.
Conclusions: Direct medical costs were significantly higher for MS cases than for controls in the VHA and were consistent with costs seen outside the VHA. Demographic and clinical factors were shown to be significant predictors of direct medical costs.
|Advisor:||Mullins, C. D.|
|Commitee:||Bever, Christopher T., Culpepper, William J., Onukwugha, Eberechukwu, Palumbo, Francis B.|
|School:||University of Maryland, Baltimore|
|Department:||Pharmaceutical Health Services Research|
|School Location:||United States -- Maryland|
|Source:||DAI-B 74/06(E), Dissertation Abstracts International|
|Subjects:||Medicine, Pharmacy sciences|
|Keywords:||Inpatients, Medical costs, Multiple sclerosis, Outpatients, Prescription drugs, Veterans Health Administration|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be